warfarin has been researched along with Wolff-Parkinson-White-Syndrome* in 2 studies
2 other study(ies) available for warfarin and Wolff-Parkinson-White-Syndrome
Article | Year |
---|---|
Rhythm versus rate control in the contemporary management of atrial fibrillation in-hospital.
Little is presently known regarding whether a rhythm-control or a rate-control strategy is more frequently used in patients hospitalized for atrial fibrillation (AF). This study was conducted to assess patient and physician characteristics associated with each treatment strategy and with the use of anticoagulants. Hospitalizations for primary diagnoses of AF were examined using hospital claims from January 2000 to December 2004. Patients who received antiarrhythmic drugs, ablation, or cardioversion for AF were categorized as receiving rhythm control. Patients managed only with beta blockers, calcium channel blockers, or digoxin were categorized as receiving rate control. Characteristics associated with rhythm compared with rate control and anticoagulant use with CHADS(2) score were determined. The study cohort included 155,731 hospitalizations from 464 hospitals. Of these, 75,397 (48%) were categorized as involving rhythm control and 80,334 (52%) as involving rate control. Care by a noncardiologist (adjusted odds ratio [OR] 0.33, 95% confidence interval [CI] 0.31 to 0.36) and increasing age >65 years (adjusted OR 0.87, 95% CI 0.86 to 0.88) were associated with lower odds of rhythm versus rate control; hypertrophic cardiomyopathy was associated with greater odds (adjusted OR 2.3, 95% CI 1.81 to 2.84) of rhythm control. Warfarin use was greater in the rhythm-control group compared with the rate-control group (adjusted OR 1.56, 95% CI 1.52 to 1.60), and warfarin use was greater with a CHADS(2) score > or =2 (unadjusted OR 1.21, 95% CI 1.19 to 1.24). In conclusion, rhythm- and rate-control strategies were used equally in patients hospitalized for AF. Some observations, such as greater use of the rate-control strategy with increasing age, were consistent with recommendations, but others, such as lower use of warfarin in the rate-control group, were not. Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Calcium Channel Blockers; Cardiomyopathy, Hypertrophic; Catheter Ablation; Digoxin; Drug Utilization; Electric Countershock; Female; Hospitalization; Humans; Male; Medicine; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Severity of Illness Index; Specialization; United States; Warfarin; Wolff-Parkinson-White Syndrome | 2008 |
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committe
Topics: Algorithms; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Cardiac Catheterization; Catheter Ablation; Electric Countershock; Heart Rate; Hemodynamics; Humans; International Normalized Ratio; Quality of Life; Risk Assessment; Thromboembolism; Warfarin; Wolff-Parkinson-White Syndrome | 2001 |